JP2004527515A - メタロプロテイナーゼ阻害剤 - Google Patents

メタロプロテイナーゼ阻害剤 Download PDF

Info

Publication number
JP2004527515A
JP2004527515A JP2002573776A JP2002573776A JP2004527515A JP 2004527515 A JP2004527515 A JP 2004527515A JP 2002573776 A JP2002573776 A JP 2002573776A JP 2002573776 A JP2002573776 A JP 2002573776A JP 2004527515 A JP2004527515 A JP 2004527515A
Authority
JP
Japan
Prior art keywords
alkyl
apci
dialkylamino
alkylamino
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002573776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004527515A5 (enExample
Inventor
アンデッシュ・エリクソン
マッティ・レピステ
ミハエル・ルンドクヴィスト
マグヌス・ムンク・アフ・ローゼンシェルト
パヴォル・ズラトイドスキー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2004527515A publication Critical patent/JP2004527515A/ja
Publication of JP2004527515A5 publication Critical patent/JP2004527515A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
JP2002573776A 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤 Withdrawn JP2004527515A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100902A SE0100902D0 (sv) 2001-03-15 2001-03-15 Compounds
PCT/SE2002/000472 WO2002074767A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009256358A Division JP5140058B2 (ja) 2001-03-15 2009-11-09 メタロプロテイナーゼ阻害剤

Publications (2)

Publication Number Publication Date
JP2004527515A true JP2004527515A (ja) 2004-09-09
JP2004527515A5 JP2004527515A5 (enExample) 2006-01-05

Family

ID=20283374

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2002573776A Withdrawn JP2004527515A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
JP2002573760A Expired - Fee Related JP4390457B2 (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
JP2002573757A Pending JP2004523581A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
JP2009256358A Expired - Fee Related JP5140058B2 (ja) 2001-03-15 2009-11-09 メタロプロテイナーゼ阻害剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2002573760A Expired - Fee Related JP4390457B2 (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
JP2002573757A Pending JP2004523581A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
JP2009256358A Expired - Fee Related JP5140058B2 (ja) 2001-03-15 2009-11-09 メタロプロテイナーゼ阻害剤

Country Status (32)

Country Link
US (8) US20040106659A1 (enExample)
EP (4) EP1370537B1 (enExample)
JP (4) JP2004527515A (enExample)
KR (4) KR100879905B1 (enExample)
CN (5) CN101602731A (enExample)
AR (2) AR035443A1 (enExample)
AT (3) ATE333454T1 (enExample)
AU (2) AU2002237632B2 (enExample)
BR (3) BR0207983A (enExample)
CA (3) CA2440630C (enExample)
CY (1) CY1107525T1 (enExample)
CZ (3) CZ20032500A3 (enExample)
DE (3) DE60213216T2 (enExample)
DK (1) DK1370556T3 (enExample)
EE (3) EE05364B1 (enExample)
ES (3) ES2267986T3 (enExample)
HU (3) HUP0400194A3 (enExample)
IL (5) IL157652A0 (enExample)
IS (3) IS6943A (enExample)
MX (3) MXPA03008181A (enExample)
MY (2) MY136141A (enExample)
NO (3) NO20034044L (enExample)
NZ (3) NZ528106A (enExample)
PL (3) PL364707A1 (enExample)
PT (1) PT1370556E (enExample)
RU (3) RU2288228C2 (enExample)
SE (1) SE0100902D0 (enExample)
SI (1) SI1370556T1 (enExample)
SK (3) SK287766B6 (enExample)
UA (3) UA77408C2 (enExample)
WO (3) WO2002074767A1 (enExample)
ZA (4) ZA200306732B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008524184A (ja) * 2004-12-15 2008-07-10 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼ阻害剤として有用なヒダントイン誘導体
JP2009531313A (ja) * 2006-03-16 2009-09-03 アストラゼネカ・アクチエボラーグ （５ｓ）−５−［４−（５−クロロ−ピリジン−２−イルオキシ）−ピペリジン−１−スルホニルメチル］−５−メチル−イミダゾリジン−２，４−ジオン（ｉ）の新規結晶形ｇおよびその中間体
JP2010077137A (ja) * 2001-03-15 2010-04-08 Astrazeneca Ab メタロプロテイナーゼ阻害剤
KR20170122720A (ko) * 2014-12-22 2017-11-06 갈라파고스 엔.브이. 골관절염의 치료를 위한 에이디에이엠티에스 억제제로서 5-[(피페라진-1-일)-3-옥소-프로필]-이미다졸리딘-2,4-디온 유도체

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
CA2447475A1 (en) 2001-05-25 2002-12-05 Chu-Biao Xue Hydantion derivatives as inhibitors of matrix metalloproteinases
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0202693D0 (sv) * 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
WO2004033632A2 (en) * 2002-10-04 2004-04-22 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US7632950B2 (en) 2003-08-18 2009-12-15 Fujifilm Finechemicals Co., Ltd Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them
WO2005090316A1 (en) * 2004-03-12 2005-09-29 Wyeth HYDANTOINS HAVING RNase MODULATORY ACTIVITY
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
JP2008512463A (ja) * 2004-09-08 2008-04-24 ボーイズ タウン ナショナル リサーチ ホスピタル マトリックスメタロプロテイナーゼ−１２に関連する糸球体基底膜疾患の治療
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
AU2005286846A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
AR051026A1 (es) * 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
WO2006101521A2 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
EP1859356B1 (en) * 2005-03-16 2019-07-10 Sensus Metering Systems Inc. Method, system, apparatus, and computer program product for determining a physical location of a sensor
JP2009513563A (ja) 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
EP1968961A2 (en) 2005-12-21 2008-09-17 Decode Genetics EHF Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
PE20071241A1 (es) * 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
US8852372B2 (en) * 2006-05-12 2014-10-07 Sca Hygiene Products Ab Pant-type absorbent article and a method for producing pant-type absorbent articles
JP4975807B2 (ja) * 2006-05-12 2012-07-11 エスセーアー・ハイジーン・プロダクツ・アーベー 弾性ラミネートおよび弾性ラミネートを製造するための方法
WO2008053199A1 (en) * 2006-10-30 2008-05-08 Astrazeneca Ab Combination therapy for the treatment of respiratory diseases
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
WO2009007747A2 (en) * 2007-07-11 2009-01-15 Astrazeneca Ab Hydantoin derivatives used as mmp12 inhibitors
WO2009064225A1 (en) 2007-11-14 2009-05-22 Sca Hygiene Products Ab Method of producing an absorbent garment, and an absorbent garment produced according to the method
WO2009064224A1 (en) 2007-11-14 2009-05-22 Sca Hygiene Products Ab Method of producing an absorbent garment, and an absorbent garment produced according to the method
FR2927330B1 (fr) * 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
WO2009134728A2 (en) 2008-04-28 2009-11-05 Revalesio Corporation Compositions and methods for treating multiple sclerosis
FR2944524B1 (fr) * 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
TWI496782B (zh) 2009-04-28 2015-08-21 Chugai Pharmaceutical Co Ltd Spiro haloperidone derivatives
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
EP2496348B1 (de) * 2009-11-06 2016-01-06 Basf Se Eisen- und manganhaltiger heterogenkatalysator und verfahren zur herstellung von olefinen durch umsetzung von kohlenmonoxid mit wasserstoff
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
RU2441069C2 (ru) * 2010-03-11 2012-01-27 Галина Ивановна Эль-Регистан Стабилизатор ферментных белков
RU2441068C2 (ru) * 2010-03-11 2012-01-27 Галина Ивановна Эль-Регистан Способ направленного изменения активности ферментных белков
RU2430371C1 (ru) * 2010-04-26 2011-09-27 Учреждение Российской академии наук Институт ядерной физики им. Г.И. Будкера Сибирского отделения РАН (ИЯФ СО РАН) Способ дифференциальной диагностики и прогноза миомы и рака эндометрия
CA2801074A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
RS61242B1 (sr) * 2012-09-04 2021-01-29 Shanghai hengrui pharmaceutical co ltd Derivati imidazolina, postupci njihove pripreme i njihove primene u medicini
US9428505B2 (en) 2012-12-10 2016-08-30 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative
BR112016010803B8 (pt) * 2013-11-13 2021-09-14 Forchem Oy Suplemento alimentar a base de ácido resínico e uso não terapêutico de um suplemento alimentar a base de ácido resínico
CN106573921B (zh) * 2013-12-31 2019-05-07 博福-益普生（天津）制药有限公司 咪唑烷-2,4-二酮衍生物
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
AU2014397042B2 (en) * 2014-06-09 2020-04-09 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative-containing pharmaceutical composition
JP6499306B2 (ja) 2014-10-24 2019-04-10 ランドス バイオファーマ インコーポレイテッド ランチオニンシンテターゼｃ様２系治療薬
RU2735600C2 (ru) * 2016-09-23 2020-11-05 Какен Фармасьютикал Ко., Лтд. Способ получения (r)-5-(3,4-дифторфенил)-5-[(3-метил-2-оксопиридин-1(2h)-ил)метил]имидазолидин-2,4-диона и промежуточное соединение для его получения
WO2021011723A1 (en) * 2019-07-18 2021-01-21 Avidence Therapeutics, Inc. Anti-osteoarthritis hydantoin compounds and related compositions and methods
HUE069818T2 (hu) * 2019-11-14 2025-04-28 Foresee Pharmaceuticals Usa Inc Mátrix metalloproteináz (MMP) inhibitorok és azok alkalmazási módszerei
PL3927427T3 (pl) 2019-12-20 2024-06-10 Nimmune Biopharma, Inc. Ligandy białka 2 podobnego do lantioniny c, komórki otrzymane z ich użyciem i terapie z ich wykorzystaniem
US12234578B2 (en) 2020-01-29 2025-02-25 Wisconsin Alumni Research Foundation Tannin composite fibers
CN116033902A (zh) * 2020-06-26 2023-04-28 伯明翰大学 治疗脊髓损伤或相关神经组织损伤的方法
CN115720578B (zh) * 2020-07-09 2025-06-13 深圳信立泰药业股份有限公司 并三环类衍生物、其制备方法及其在医药上的应用
CN112574193B (zh) * 2020-12-31 2022-05-17 南京医科大学 一类口服gsnor抑制剂及其药物用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2327890A (en) * 1940-04-17 1943-08-24 Parke Davis & Co Substituted phenoxyalkyl ethers
US2745875A (en) * 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) * 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) * 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
CS152617B1 (enExample) 1970-12-29 1974-02-22
CS151744B1 (enExample) 1971-01-19 1973-11-19
US3849574A (en) * 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS6172762A (ja) 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd 光学活性ヒダントイン類の製造法
JPS61212292A (ja) 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc Ｄ−α−アミノ酸の製造方法
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
GB8618559D0 (en) 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
JPH0279879A (ja) 1988-09-17 1990-03-20 Canon Inc 画像形成装置
US4983771A (en) 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
IL99957A0 (en) 1990-11-13 1992-08-18 Merck & Co Inc Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
NL9201230A (nl) 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
JPH07105549A (ja) 1993-09-30 1995-04-21 Canon Inc 光学的情報記録再生方法及び光学的情報記録再生装置
EP0729472A4 (en) 1993-11-16 1997-03-19 Merck & Co Inc PIPERIDINYL FIGHTING SULFONYLE AS OXYTOCIN ANTAGONISTS
JP2866743B2 (ja) 1994-01-31 1999-03-08 フアイザー・インコーポレイテツド 神経保護化合物
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
NZ322565A (en) 1995-11-22 1999-11-29 Darwin Discovery Ltd Mercaptoalkykpeptidyl compounds having an imidazole substitutent and their use as inhibitors of matrix metalloproteinases and tumor necrosis factor
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
AU4812697A (en) 1996-10-22 1998-05-15 Pharmacia & Upjohn Company Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors
IL132170A0 (en) * 1997-05-06 2001-03-19 Novo Nordisk As Novel heterocyclic compounds
DK0877019T3 (da) * 1997-05-09 2002-04-08 Hoechst Ag Substituerede diaminocarboxylsyrer
ATE302200T1 (de) 1997-06-21 2005-09-15 Roche Diagnostics Gmbh Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DK1001930T3 (da) 1997-07-31 2003-03-24 Abbott Lab N-hydroxyformamidderivater som inhibitorer af matrix-metalloproteinaser
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
KR100609926B1 (ko) 1997-11-12 2006-08-04 다윈 디스커버리 리미티드 엠엠피와 티엔에프 억제 활성을 갖는 히드록삼산 및카르복실산 유도체
IL137465A0 (en) 1998-02-04 2001-07-24 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
WO1999058528A1 (en) * 1998-05-14 1999-11-18 Bristol-Myers Squibb Pharma Company. Substituted aryl hydroxamic acids as metalloproteinase inhibitors
JP2002516904A (ja) * 1998-06-03 2002-06-11 ジーピーアイ ニル ホールディングス インコーポレイテッド Ｎ−複素環式カルボン酸またはカルボン酸等配電子体のｎ−結合スルホンアミド
US6429213B1 (en) * 1998-06-17 2002-08-06 Bristol Myers Squibb Pharma Co Cyclic hydroxamic acids as metalloproteinase inhibitors
FR2782082B3 (fr) 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
JP2000127349A (ja) * 1998-08-21 2000-05-09 Komori Corp 凹版印刷機
EP1107953A1 (en) 1998-08-29 2001-06-20 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as proteinase inhibitors
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
AU764586B2 (en) 1998-10-07 2003-08-21 Yazaki Corporation Sol-gel process using porous mold
DK1004578T3 (da) 1998-11-05 2004-06-28 Pfizer Prod Inc 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
HUP0104987A3 (en) 1998-12-18 2002-09-30 Axys Pharmaceuticals Inc South Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them
EP1150975A1 (en) * 1998-12-31 2001-11-07 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6340691B1 (en) * 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
EP1149843A4 (en) 1999-01-28 2012-06-06 Chugai Pharmaceutical Co Ltd SUBSTITUTED PHENETHYLAMINE DERIVATIVES
US6294694B1 (en) 1999-06-04 2001-09-25 Wisconsin Alumni Research Foundation Matrix metalloproteinase inhibitors and method of using same
GB9916562D0 (en) 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
US20020006920A1 (en) 1999-07-22 2002-01-17 Robinson Ralph Pelton Arylsulfonylamino hydroxamic acid derivatives
US6266453B1 (en) 1999-07-26 2001-07-24 Computerized Medical Systems, Inc. Automated image fusion/alignment system and method
DK1078923T3 (da) * 1999-08-02 2006-07-10 Hoffmann La Roche Fremgangsmåde til fremstilling af benzothiophenderivater
BR0013143A (pt) 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
JP3710964B2 (ja) 1999-08-26 2005-10-26 富士通株式会社 ディスプレイデバイスのレイアウト設計方法
SE9904044D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
AU2001278709A1 (en) 2000-08-11 2002-02-25 Kaken Pharmaceutical Co..Ltd. 2,3-diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage
US20020065219A1 (en) 2000-08-15 2002-05-30 Naidu B. Narasimhulu Water soluble thiazolyl peptide derivatives
US20020091107A1 (en) * 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
WO2002020515A1 (en) 2000-09-08 2002-03-14 Abbott Laboratories Oxazolidinone antibacterial agents
EP1191024A1 (en) 2000-09-22 2002-03-27 Harald Tschesche Thiadiazines and their use as inhibitors of metalloproteinases
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
WO2002074750A1 (en) * 2001-03-15 2002-09-26 Astrazeneca Ab Metalloproteinase inhibitors
CA2447475A1 (en) 2001-05-25 2002-12-05 Chu-Biao Xue Hydantion derivatives as inhibitors of matrix metalloproteinases
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
JP4485941B2 (ja) 2002-06-05 2010-06-23 株式会社カネカ 光学活性α−メチルシステイン誘導体の製造方法
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0202693D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
SE0202692D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0221250D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US6890913B2 (en) * 2003-02-26 2005-05-10 Food Industry Research And Development Institute Chitosans
US20040266832A1 (en) 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine
TWI220073B (en) 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401763D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200800954A (en) 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200831488A (en) 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010077137A (ja) * 2001-03-15 2010-04-08 Astrazeneca Ab メタロプロテイナーゼ阻害剤
JP2008524184A (ja) * 2004-12-15 2008-07-10 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼ阻害剤として有用なヒダントイン誘導体
JP2009531313A (ja) * 2006-03-16 2009-09-03 アストラゼネカ・アクチエボラーグ （５ｓ）−５−［４−（５−クロロ−ピリジン−２−イルオキシ）−ピペリジン−１−スルホニルメチル］−５−メチル−イミダゾリジン−２，４−ジオン（ｉ）の新規結晶形ｇおよびその中間体
KR20170122720A (ko) * 2014-12-22 2017-11-06 갈라파고스 엔.브이. 골관절염의 치료를 위한 에이디에이엠티에스 억제제로서 5-[(피페라진-1-일)-3-옥소-프로필]-이미다졸리딘-2,4-디온 유도체
JP2018502906A (ja) * 2014-12-22 2018-02-01 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 変形性関節症の治療のためのａｄａｍｔｓ阻害剤としての５−［（ピペラジン−１−イル）−３−オキソ−プロピル］−イミダゾリジン−２，４−ジオン誘導体
KR102711990B1 (ko) 2014-12-22 2024-10-02 갈라파고스 엔.브이. 골관절염의 치료를 위한 에이디에이엠티에스 억제제로서 5-[(피페라진-1-일)-3-옥소-프로필]-이미다졸리딘-2,4-디온 유도체

Also Published As

Publication number Publication date
MXPA03008181A (es) 2003-12-12
KR20030082987A (ko) 2003-10-23
EP1676846A2 (en) 2006-07-05
CN101602731A (zh) 2009-12-16
ZA200306731B (en) 2004-11-29
UA78502C2 (en) 2007-04-10
EE200300445A (et) 2003-12-15
NZ528107A (en) 2005-06-24
SK10962003A3 (sk) 2004-03-02
HUP0400327A2 (hu) 2005-01-28
ATE333454T1 (de) 2006-08-15
ZA200306734B (en) 2004-11-29
PL365099A1 (en) 2004-12-27
US20110003853A1 (en) 2011-01-06
US7666892B2 (en) 2010-02-23
US7368465B2 (en) 2008-05-06
CN1962641A (zh) 2007-05-16
NZ528106A (en) 2005-03-24
WO2002074748A8 (en) 2004-04-22
AU2002237626B2 (en) 2007-05-17
NO20034044L (no) 2003-11-10
JP2010077137A (ja) 2010-04-08
SI1370556T1 (sl) 2006-10-31
PL364707A1 (en) 2004-12-13
EE200300449A (et) 2003-12-15
EP1370556B1 (en) 2006-07-19
US20040106659A1 (en) 2004-06-03
ES2357138T3 (es) 2011-04-19
WO2002074751A1 (en) 2002-09-26
HUP0400194A3 (en) 2004-10-28
ZA200306737B (en) 2004-11-29
NO327114B1 (no) 2009-04-27
RU2003127734A (ru) 2005-03-20
RU2003127735A (ru) 2005-03-20
CN1509276A (zh) 2004-06-30
KR20080071210A (ko) 2008-08-01
CA2440473A1 (en) 2002-09-26
HK1091492A1 (en) 2007-01-19
IS6942A (is) 2003-09-09
EP1676846B1 (en) 2010-12-29
PL205315B1 (pl) 2010-04-30
HK1059932A1 (en) 2004-07-23
KR20030082986A (ko) 2003-10-23
UA77667C2 (en) 2007-01-15
CA2440630C (en) 2011-09-27
SK287834B6 (sk) 2011-12-05
IL157656A (en) 2010-11-30
US8153673B2 (en) 2012-04-10
SE0100902D0 (sv) 2001-03-15
DE60238794D1 (de) 2011-02-10
EE200300451A (et) 2003-12-15
BR0207983A (pt) 2004-06-15
CA2440630A1 (en) 2002-09-26
IL157657A0 (en) 2004-03-28
US20080262045A1 (en) 2008-10-23
WO2002074767A8 (en) 2004-04-22
NZ528140A (en) 2005-02-25
RU2003127733A (ru) 2005-03-20
ZA200306732B (en) 2004-11-29
JP5140058B2 (ja) 2013-02-06
CY1107525T1 (el) 2013-03-13
ES2352246T3 (es) 2011-02-16
IL157652A (en) 2010-11-30
US7754750B2 (en) 2010-07-13
CZ20032500A3 (cs) 2004-02-18
MXPA03008177A (es) 2003-12-12
MY136789A (en) 2008-11-28
EP1370556A1 (en) 2003-12-17
PL364706A1 (en) 2004-12-13
CA2440631A1 (en) 2002-09-26
SK10952003A3 (sk) 2004-05-04
EP1370534A1 (en) 2003-12-17
CA2440473C (en) 2011-08-30
CN100526307C (zh) 2009-08-12
PT1370556E (pt) 2006-11-30
CN1962641B (zh) 2012-07-04
MY136141A (en) 2008-08-29
WO2002074767A1 (en) 2002-09-26
BR0208104A (pt) 2004-03-02
ATE484496T1 (de) 2010-10-15
EE05431B1 (et) 2011-06-15
IS6943A (is) 2003-09-09
SK287766B6 (sk) 2011-09-05
AR035695A1 (es) 2004-06-23
DK1370556T3 (da) 2006-10-30
SK10922003A3 (sk) 2004-05-04
US20080306065A1 (en) 2008-12-11
IL157652A0 (en) 2004-03-28
HK1060121A1 (en) 2004-07-30
JP2004523581A (ja) 2004-08-05
AU2002237632B2 (en) 2007-05-10
RU2288228C2 (ru) 2006-11-27
EE05364B1 (et) 2010-12-15
WO2002074748A1 (en) 2002-09-26
HUP0400194A2 (hu) 2004-07-28
IS6946A (is) 2003-09-10
CN1509272A (zh) 2004-06-30
CN1509286A (zh) 2004-06-30
NO20034044D0 (no) 2003-09-12
US20040138276A1 (en) 2004-07-15
NO20034045D0 (no) 2003-09-12
KR100886315B1 (ko) 2009-03-04
NO20034042L (no) 2003-11-10
JP4390457B2 (ja) 2009-12-24
HUP0400202A3 (en) 2004-10-28
US20080171882A1 (en) 2008-07-17
HUP0400202A2 (hu) 2004-08-30
EP1676846A3 (en) 2006-07-26
ATE493406T1 (de) 2011-01-15
MXPA03008191A (es) 2004-01-29
AR035443A1 (es) 2004-05-26
EP1370537B1 (en) 2010-10-13
CN1269804C (zh) 2006-08-16
US7625934B2 (en) 2009-12-01
HUP0400327A3 (en) 2005-06-28
BR0207984A (pt) 2004-06-15
JP2004523583A (ja) 2004-08-05
US20040127528A1 (en) 2004-07-01
US7427631B2 (en) 2008-09-23
CZ20032499A3 (cs) 2004-03-17
US20100273849A1 (en) 2010-10-28
DE60213216T2 (de) 2007-07-12
NO326087B1 (no) 2008-09-15
DE60237965D1 (en) 2010-11-25
UA77408C2 (en) 2006-12-15
CZ20032497A3 (cs) 2004-02-18
ES2267986T3 (es) 2007-03-16
RU2285695C2 (ru) 2006-10-20
KR20030082989A (ko) 2003-10-23
NO20034042D0 (no) 2003-09-12
EP1370537A1 (en) 2003-12-17
CN1304377C (zh) 2007-03-14
DE60213216D1 (en) 2006-08-31
NO20034045L (no) 2003-11-10
RU2293729C2 (ru) 2007-02-20
IL157656A0 (en) 2004-03-28
KR100879905B1 (ko) 2009-01-21

Similar Documents

Publication Publication Date Title
JP5140058B2 (ja) メタロプロテイナーゼ阻害剤
US20040147573A1 (en) Metalloproteinase inhibitors
AU2002237626A1 (en) Metalloproteinase inhibitors
SK2702001A3 (en) ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITINGì (54) AGENTS (MMP)
JP4256095B2 (ja) メタロプロテイナーゼの阻害剤としてのピペリジン−およびピペラジン置換ｎ−ヒドロキシホルムアミド類
TWI329637B (en) Compounds
HK1059932B (en) Metalloproteinase inhibitors
AU2002237629A1 (en) Metalloproteinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090409

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090513

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091109

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20091225